This is important as GLP‐2 is currently considered in the treatment of short bowel syndrome induced intestinal failure (Jeppesen et al., 1999, 2001, 2005, 2009, 2011), Crohn's disease (Buchman et al., 2010), inflammatory bowel disease (Alavi et al., 2000; Xiao et al., 2000), chemotherapeutic enteritis (Tavakkolizadeh et al., 2000), intestinal ischemia (Guan et al., 2005; Moreira et al., 2024; Rajeevprasad et al., 2000), and in combination with GLP‐1, also obesity (Pálsson et al., 2024). This evidence concerns the gene GLP1R and obesity disorder.